39
Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets Simon Berry

ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Embed Size (px)

Citation preview

Page 1: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

Simon Berry

Page 2: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

ColaLife is a charity registered in the UKCharity number: 1142516

• Small, independent and catalytic• Focus on saving children’s lives• Looking for global impact through

• Innovation• Generating robust evidence• Sharing findings and learning• Influencing healthcare strategies

• No commercial interest

2009

2010

2011

2012

2013

1985What is ColaLife and who am I?

Page 3: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 4: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 5: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Coca-Cola gets to most places, life-saving medicines don’t

Page 6: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Under 5 mortality is unacceptably high…

Page 7: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

…when compared with more developed countries

Page 8: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Diarrhoea is the second biggest killer

Diarrhoea

Page 9: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 10: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Sep 2010 | Enrolled into the J&J Innovation Bootcamp

Kris Pintens

Michelle Akande

Johan Offermans

Jane Berry

Alexander Bielders Simon Berry

Page 11: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Some of the ColaLife funders

Isenberg Family Charitable Foundation

Page 12: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Awards | The Kit Yamoyo has won many global awards

Page 13: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 14: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Dec 2011

The trial timeline

Page 15: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Mimicking Coca-Cola – creating a product people WANT

What we learnt

Litre sachets are too big

Measuring water was an issue

Willingness to pay

Preferred branding

Page 16: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Kit Yamoyo• Attractive• Affordable• Packaging is also:

• A measuring device for the water

• A mixing device• A storage device (the

soap tray is a lid)• A cup• And can be re-used

Page 17: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Kit Yamoyo – why the funny shape?

Page 18: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Mimicking Coca-Cola – Community-based marketing

Page 19: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

Page 20: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

Page 21: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 22: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 23: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

Page 24: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

Page 25: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

Page 26: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

Page 27: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

Page 28: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

Page 29: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 30: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Manufacture

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

Value

Kit Yamoyos

Demand PULLED the Kit Yamoyo into rural communities

Page 31: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

What we learned (1)

1. Value chain• Perceived value• Delivers to expectations (use of standards)• Product design• Attractive• Aspirational

• Affordable• Profitable for all

2. Sensible use of subsidy• Top-end subsidy (non-corruption of the value chain)• Use of vouchers

Page 32: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

What we learned (2)

3. Behaviour change works better with a product4. Organisations already exist but may need:• Bringing together in new ways• Capacity building

5. Partnership and shared risk• Donor support for trials and start-up• Donor support for awareness raising and training• Private sector for sustainable production

6. Think about multi-channels to market• Are the private sector needs different from the public sector

needs?

Page 33: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 34: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Ways to understand and improve Access

Various Access models (eg WHO/UNICEF) consider 4 or 5 facets of Access, including:

• Availability• Accessibility• Acceptability• Affordability• Adherence

Page 35: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Insights for Janssen? - A wider view of Access?

Access considerations might usefully be expanded:

1. Asking the customer• Review products destined for African market• Find out what people WANT not on what you think they NEED

2. Adapting better to the local context• Insights from working more closely with NGOs, local private sector

3. Advocacy with government, regulators, pharmacists4. Deliver Advantage

• All along the value chain – ‘price minus costing’ not ‘cost plus pricing’5. Awareness-raising

• Not just advertising• Invest in customer education, retailer or wholesaler training

6. Aspiration• Produce products that people aspire to use• The poor are as brand and quality aware as anybody else

Jane Berry
you could take this bullet off the slide if you can remember the examples
Page 36: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our starting point

Management Board Update, Janssen, Beerse, Belgium ColaLife learning and opportunities in emerging markets

26-Aug-15

Implications for Janssen

Our partnership so far What we did

Our partnership next stepsWhat we learned

3

5 6

1

4

2

Page 37: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Our partnership – possible next steps

1. It’s about partnership for global impact (not funding)

2. Sharing our learning to impact on the way Janssen does business in Africa (open access with support from ColaLife)

3. Use ColaLife as a catalyst for change• The grain in the oyster / the yeast in the bread

4. For this to work ColaLife would need a point of contact with the Management Board and Global Health Team

Page 38: ColaLife Presentation to the Janssen Management Board, 26-Aug-15

Questions?Comments?

Page 39: ColaLife Presentation to the Janssen Management Board, 26-Aug-15